share_log

EFFECT: Others

EFFECT: Others

EFFECT:其他
美股SEC公告 ·  2024/10/07 18:03

Moomoo AI 已提取核心訊息

NeuroSense Therapeutics Ltd., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on October 4, 2024. The notice, bearing the accession number 0001213900-24-083478, indicates that the company's submission type POS AM has been officially accepted. The CIK number associated with NeuroSense Therapeutics is 0001875091, and the SEC file number for this notice is 333-273375.
NeuroSense Therapeutics Ltd., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on October 4, 2024. The notice, bearing the accession number 0001213900-24-083478, indicates that the company's submission type POS AM has been officially accepted. The CIK number associated with NeuroSense Therapeutics is 0001875091, and the SEC file number for this notice is 333-273375.
NeuroSense Therapeutics Ltd., 一家在美國上市的公司,於2024年10月4日收到了美國證券交易委員會(SEC)的有效通知。該通知,附帶訪問號0001213900-24-083478,表明該公司的提交類型pos Am已經被正式接受。與 NeuroSense Therapeutics 相關的 CIk 號碼爲0001875091,此通知的 SEC 文件號爲333-273375。
NeuroSense Therapeutics Ltd., 一家在美國上市的公司,於2024年10月4日收到了美國證券交易委員會(SEC)的有效通知。該通知,附帶訪問號0001213900-24-083478,表明該公司的提交類型pos Am已經被正式接受。與 NeuroSense Therapeutics 相關的 CIk 號碼爲0001875091,此通知的 SEC 文件號爲333-273375。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息